医学传播公司和行业资助。

Mailman School of Public Health, Columbia University, New York, New York.

College of Physicians and Surgeons, Columbia University, New York, New York.

JAMA. 2013 Dec 18;310(23):2554-8. doi: 10.1001/jama.2013.281638.

IMPORTANCE

Medical communication companies (MCCs) are among the most significant health care stakeholders, supported mainly by drug and device companies. How MCCs share or protect physicians' personal data requires greater transparency.

OBJECTIVE

To explore the financial relationships between MCCs and drug and device companies, to describe the characteristics of the large MCCs, and to explore whether they accurately represent themselves to physicians.

DESIGN

We combined data from the 2010 grant registries of 14 pharmaceutical and device companies; grouped recipients into categories such as MCCs, academic medical centers, disease-targeted advocacy organizations, and professional associations; and created a master list of 19,272 grants.

MAIN OUTCOMES AND MEASURES

Determine the distribution of funds from drug and device companies to various entities and assess the characteristics of large MCCs.

RESULTS

Of the 6493 recipients of more than $657 million grant awards from drug and device companies, 18 of 363 MCCs received 26%, academic medical centers received 21%, and disease-targeted organizations received 15%. For-profit MCCs received 77% of funds (208 of 363). Among the top 5% of MCCs, 14 of 18 were for-profit. All 18 offered continuing medical education: 14 offered live and 17 offered online CME courses. All required physicians to provide personal data. Ten stated that they shared information with unnamed third parties. Eight stated they did not share information, but almost all added exceptions. None required explicit physician consent to their sharing policies.

CONCLUSIONS AND RELEVANCE

Medical communication companies receive substantial support from drug and device companies. Physicians who interact with MCCs should be aware that all require personal data from the physician and some share these data with unnamed third parties.

重要性

医疗传播公司（MCC）是最重要的医疗保健利益相关者之一，主要由制药和医疗器械公司支持。MCC 如何共享或保护医生的个人数据需要更大的透明度。

目的

探索 MCC 与制药和医疗器械公司之间的财务关系，描述大型 MCC 的特点，并探讨它们是否如实向医生介绍自己。

设计

我们结合了 14 家制药和医疗器械公司 2010 年赠款登记处的数据；将受赠方分为 MCC、学术医疗中心、疾病靶向倡导组织和专业协会等类别；并创建了一个包含 19272 项赠款的主列表。

主要结果和措施

确定制药和医疗器械公司向各实体分配资金的情况，并评估大型 MCC 的特点。

结果

在从制药和医疗器械公司获得超过 6570 万美元赠款的 6493 名受赠方中，18 家 MCC 中的 363 家获得了 26%的资金，学术医疗中心获得了 21%，疾病靶向组织获得了 15%。营利性 MCC 获得了 77%的资金（363 家中有 208 家）。在排名前 5%的 MCC 中，18 家是营利性的。所有 18 家都提供继续医学教育：14 家提供现场课程，17 家提供在线 CME 课程。所有 MCC 都要求医生提供个人数据。其中 10 家表示他们与不知名的第三方共享信息。8 家表示他们不共享信息，但几乎所有 MCC 都添加了例外情况。没有一家要求医生明确同意其共享政策。